|
EP1528101A1
(en)
*
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalized avian cell lines for virus production
|
|
ES2329607T3
(es)
|
2004-02-23 |
2009-11-27 |
Crucell Holland B.V. |
Metodos de purificacion de virus.
|
|
DK1869171T4
(en)
|
2005-04-11 |
2016-01-18 |
Crucell Holland Bv |
Virus cleaning using ultrafiltration
|
|
DE102005054628A1
(de)
|
2005-11-16 |
2007-05-24 |
Cevec Pharmaceuticals Gmbh |
Verfahren zur Herstellung von permanenten humanen Zelllinien
|
|
ES2755386T5
(es)
|
2006-08-28 |
2023-04-05 |
Ares Trading Sa |
Proceso para la purificación de proteínas que contienen fragmentos Fc
|
|
CA2742474C
(en)
|
2008-11-03 |
2016-05-31 |
Crucell Holland B.V. |
Method for the production of adenoviral vectors
|
|
DE102009003439A1
(de)
|
2009-02-05 |
2010-08-26 |
Cevec Pharmaceuticals Gmbh |
Neue permanente humane Zelllinie
|
|
KR101805938B1
(ko)
|
2009-10-15 |
2018-01-10 |
얀센 백신스 앤드 프리벤션 비.브이. |
고밀도 세포 배양액에서 아데노바이러스의 정제 방법
|
|
AU2010305765B2
(en)
|
2009-10-15 |
2015-07-02 |
Crucell Holland B.V. |
Method for the purification of adenovirus particles
|
|
JP5250155B2
(ja)
|
2010-02-15 |
2013-07-31 |
クルセル ホランド ベー ヴェー |
Ａｄ２６アデノウイルスベクターの製造方法
|
|
MX337687B
(es)
|
2010-08-16 |
2016-03-15 |
Cevec Pharmaceuticals Gmbh |
Linea celular de amniocitos humanos permanente para la produccion de virus de influenza.
|
|
KR101427200B1
(ko)
*
|
2011-11-24 |
2014-08-07 |
주식회사 바이로메드 |
아데노바이러스 생산 신규 세포주 및 그의 용도
|
|
CA2864956C
(en)
|
2012-03-12 |
2021-11-09 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
AP2014007993A0
(en)
|
2012-03-22 |
2014-10-31 |
Crucell Holland Bv |
Vaccine against RSV
|
|
EP2662451A1
(en)
*
|
2012-05-07 |
2013-11-13 |
Stefan Kochanek |
Nucleic acid construct and use of the same
|
|
WO2014060594A1
(en)
*
|
2012-10-19 |
2014-04-24 |
Cevec Pharmaceuticals Gmbh |
Production of a hcmv based vaccine in human amniocyte cell lines
|
|
EP2722337A1
(en)
|
2012-10-19 |
2014-04-23 |
CEVEC Pharmaceuticals GmbH |
Production of a HCMV based vaccine in human amniocyte cell lines
|
|
SG11201508567XA
(en)
|
2013-04-25 |
2015-11-27 |
Crucell Holland Bv |
Stabilized soluble prefusion rsv f polypeptides
|
|
CN105408348B
(zh)
|
2013-06-17 |
2021-07-06 |
扬森疫苗与预防公司 |
稳定化的可溶性融合前rsv f多肽
|
|
DE112014003136A5
(de)
|
2013-07-01 |
2016-04-21 |
Charité - Universitätsmedizin Berlin |
Immortalisierte humane Chorionzelllinie sowie Verfahren zur Immortalisierung humaner Chorionzellen
|
|
WO2016071306A1
(en)
|
2014-11-04 |
2016-05-12 |
Crucell Holland B.V. |
Therapeutic hpv16 vaccines
|
|
EP3042952A1
(en)
|
2015-01-07 |
2016-07-13 |
CEVEC Pharmaceuticals GmbH |
O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
|
|
CN107466324B
(zh)
|
2015-04-14 |
2022-01-14 |
扬森疫苗与预防公司 |
具有双向启动子的表达两种转基因的重组腺病毒
|
|
EA039065B1
(ru)
|
2015-07-07 |
2021-11-29 |
Янссен Вэксинс Энд Превеншн Б.В. |
Вакцина против rsv
|
|
US10457708B2
(en)
|
2015-07-07 |
2019-10-29 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F polypeptides
|
|
MY195389A
(en)
|
2015-08-20 |
2023-01-18 |
Janssen Vaccines & Prevention Bv |
Therapeutic HPV18 Vaccines
|
|
EP3808374A1
(en)
|
2016-04-05 |
2021-04-21 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection
|
|
CN109069612A
(zh)
|
2016-04-05 |
2018-12-21 |
扬森疫苗与预防公司 |
针对rsv的疫苗
|
|
US10517944B2
(en)
|
2016-05-02 |
2019-12-31 |
Janssen Vaccines & Prevention B.V. |
Therapeutic HPV vaccine combinations
|
|
BR112018072865A2
(pt)
|
2016-05-12 |
2019-04-30 |
Janssen Vaccines & Prevention B.V. |
promotor bidirecional potente e equilibrado
|
|
PE20190110A1
(es)
|
2016-05-30 |
2019-01-15 |
Janssen Vaccines And Prevention B V |
Proteinas f de prefusion del vrs estabilizadas
|
|
EP3472327B1
(en)
|
2016-06-20 |
2020-08-19 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
|
EP3484506A1
(en)
|
2016-07-14 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Hpv vaccines
|
|
CN110268061B
(zh)
|
2017-02-09 |
2024-07-16 |
扬森疫苗与预防公司 |
用于表达异源基因的有效的短启动子
|
|
EP3382014A1
(en)
|
2017-03-29 |
2018-10-03 |
CEVEC Pharmaceuticals GmbH |
Recombinant glycoproteins with reduced antennary fucosylation
|
|
CA3061278A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
BR112020004143A2
(pt)
|
2017-09-15 |
2020-09-01 |
Janssen Vaccines & Prevention B.V. |
método para a indução segura de imunidade contra vírus sincicial respiratório (rsv)
|
|
AU2018359492B2
(en)
|
2017-10-31 |
2023-12-14 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
MX2020004487A
(es)
|
2017-10-31 |
2020-08-13 |
Janssen Vaccines & Prevention Bv |
Adenovirus y usos de estos.
|
|
US11236361B2
(en)
|
2017-10-31 |
2022-02-01 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
EP3704256A1
(en)
|
2017-10-31 |
2020-09-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
|
PH12021550974A1
(en)
|
2018-11-13 |
2022-05-02 |
Janssen Vaccines & Prevention Bv |
Stablized pre-fusion rsv f proteins
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
EP3736286A1
(en)
|
2019-05-09 |
2020-11-11 |
Biotest AG |
Single chain factor viii molecule
|
|
AU2020275910A1
(en)
|
2019-05-15 |
2021-11-04 |
Janssen Vaccines & Prevention B.V. |
Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
|
|
JP2022532723A
(ja)
|
2019-05-15 |
2022-07-19 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
季節性インフルエンザワクチン及びアデノウイルス系呼吸器合胞体ウイルスワクチンの共投与
|
|
JP2022546525A
(ja)
|
2019-09-02 |
2022-11-04 |
ビオテスト・アクチエンゲゼルシャフト |
延長された半減期を有する第ｖｉｉｉ因子タンパク質
|
|
EP3785726A1
(en)
|
2019-09-02 |
2021-03-03 |
Biotest AG |
Factor viii protein with increased half-life
|
|
EP4038088A1
(en)
|
2019-10-03 |
2022-08-10 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
|
EP4061405A1
(en)
|
2019-11-18 |
2022-09-28 |
Janssen Biotech, Inc. |
Vaccines based on mutant calr and jak2 and their uses
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
WO2021165226A1
(en)
|
2020-02-17 |
2021-08-26 |
Biotest Ag |
Subcutaneous administration of factor viii
|
|
EP4175721A1
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
US20230035403A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Method For Determining Responsiveness To Prostate Cancer Treatment
|
|
CA3197730A1
(en)
|
2020-10-15 |
2022-04-21 |
F. Hoffman-La Roche Ag |
Nucleic acid constructs for va rna transcription
|
|
AU2021363098A1
(en)
|
2020-10-15 |
2023-05-18 |
F. Hoffmann-La Roche Ag |
Nucleic acid constructs for simultaneous gene activation
|
|
AU2022373653A1
(en)
|
2021-10-18 |
2024-05-02 |
Regeneron Pharmaceuticals, Inc. |
Eukaryotic cells comprising adenovirus-associated virus polynucleotides
|
|
WO2023198685A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Method for determining aav genomes
|
|
CN119256220A
(zh)
|
2022-05-23 |
2025-01-03 |
豪夫迈·罗氏有限公司 |
用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法
|
|
EP4532737A1
(en)
|
2022-06-03 |
2025-04-09 |
F. Hoffmann-La Roche AG |
Method for producing recombinant aav particles
|
|
WO2024013239A1
(en)
|
2022-07-14 |
2024-01-18 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
|
CA3264505A1
(en)
|
2022-09-12 |
2024-03-21 |
Hoffmann La Roche |
METHOD FOR SEPARING SOLID AND EMPTY VAA PARTICLES
|
|
IL322001A
(en)
|
2023-02-07 |
2025-09-01 |
Hoffmann La Roche |
Method for detecting antibodies to anti-AAV particles
|
|
AU2024239386A1
(en)
|
2023-03-21 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for the production of recombinant aav particle preparations
|
|
CN117487761A
(zh)
*
|
2023-09-25 |
2024-02-02 |
南京农业大学 |
表达Cre基因猪骨髓巨噬细胞系的构建方法及其应用
|
|
WO2025158316A1
(en)
|
2024-01-26 |
2025-07-31 |
Janssen Biotech, Inc. |
Ovarian neoantigens and use thereof
|
|
WO2025168663A1
(en)
|
2024-02-09 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant adeno-associated viral particles
|